BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
366
Data completeness
6/8 — Strong
Priority Review
OPDUALAG (nivolumab and relatlimab-rmbw) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2022.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDUALAG is a fixed-dose combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3), two monoclonal antibodies that work synergistically to block immune checkpoint pathways. It is approved for melanoma and other solid tumors where dual checkpoint inhibition enhances T-cell activation. The combination targets both PD-1 and LAG-3 receptors to overcome tumor immune evasion.
$4MPart D
PeakOPDUALAG is in peak commercial phase with modest Medicare Part D utilization, indicating either early market penetration or niche positioning; teams should expect stable-to-growing headcount in sales and marketing.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (366)
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Started Apr 2026
60 enrolled
Diffuse Pleural MesotheliomaGastroesophageal CarcinomaUrothelial Carcinoma
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Started Apr 2026
15 enrolled
Metastatic MelanomaLiver Metastases
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Started Mar 2026
690 enrolled
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Started Feb 2026
240 enrolled
Relapsed/Refractory Small Cell Lung Cancer
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Started Dec 2025
240 enrolled
Non-Small Cell Lung Cancer
Worked on OPDUALAG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.